Research Departments & Organizations
Cutaneous T cell lymphoma is the most common malignancy of lymphocytes in adults. Our group studies the basic biology of the malignant cells of CTCL and relates cellular properties to the clinical course of the disease. We have developed an active immunotherapy program, a biological modifier system approved as a standard treatment for advanced CTCL by the FDA and now used in over 100 therapy centers worldwide. This treatment, known as "photopheresis" has been recently shown by us to work through a mechanism of increasing immunogenicity of class I associated tumor specific peptides including those derived from the clone specific T cell receptors. We are investigating means of increasing the expression of these peptide antigens and characterizing the cytotoxic T cell response against them.
Specialized Terms: Cutaneous T cell lymphoma (CTCL); Human T cell physiology; Immunobiology of normal and diseased skin
Extensive Research Description
Under the leadership of Dr. Edelson CTCL cells have been characterized and new and effective therapies developed. CTCL was found to be a cancer of "cutaneous T cells," which migrate to and infiltrate the skin. Dr. Edelson and his colleagues have developed an immunotherapy known as "Photopheresis," which is FDA approved and used to treat CTCL and other T cell mediated diseases in more than 100 centers worldwide.
Cancer Immunization China (2008)
Dr. Richard Edelson is working with colleagues at Shanghai University to develop selective immunization against immunogenic cancers.
Immunization Against Immunogenic Cancers Israel (2008)
International Health Yale School of Medicine work in selective immunization against immunogenic cancers
Immunization Against Immunogenic Cancers United Kingdom (2008)
Professor Edelson conducts collaborative work with colleagues from King's College, London, on selective immunization against immunogenic cancers.
Immunogenic Cancers Switzerland (2008)
International Health Yale School of Medicine work in selective immunization against immunogenic cancers.
Immunogenic Cancers France (2008)
Professor Edelson conducts collaborative work with French researchers at the Hospital St. Louis in France on selective immunization against immunogenic cancers.
Immunogenic Cancers Germany (2008)
Professor Casten conducted collaborative work with researchers at the University of Munich on selective immunization against immunogenic cancers
FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.
Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Molecular Imaging And Biology : MIB : The Official Publication Of The Academy Of Molecular Imaging 2008, 10:74-81. 2008
Berger CL, Shofner J, Vasquez JG, Mariwalla K, Edelson RL. Cancer Immunotherapy. Cancer Therapy 4:81-98, 2006. 2006
Langerhans cells: mediators of immunity and tolerance.
Berger CL, Vasquez JG, Shofner J, Mariwalla K, Edelson RL. Langerhans cells: mediators of immunity and tolerance. The International Journal Of Biochemistry & Cell Biology 2006, 38:1632-6. 2006
Transimmunization for cutaneous T cell lymphoma: a Phase I study.
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leukemia & Lymphoma 2006, 47:1495-503. 2006